The reason for this is that chromosomal rearrangements in the genes of ALK and ROS1 induce fusion kinases with constitutive activity.[119] This in turn leads to the triggering of downstream signaling pathways that contribute to the development and progression of NSCLC.[120] Lorlatinib is therefore used for the treatment of ALK‐positive NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.